172 related articles for article (PubMed ID: 26047084)
1. Letter to the Editor: Re: Neurobehavioral Deficits, Diseases, and Associated Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union.
Middelbeek RJ; Veuger SA
J Clin Endocrinol Metab; 2015 Jun; 100(6):L52-3. PubMed ID: 26047084
[No Abstract] [Full Text] [Related]
2. Response to the Letter by Middlebeek and Veuger.
Bellanger M; Demeneix B; Grandjean P; Zoeller RT; Trasande L
J Clin Endocrinol Metab; 2015 Jun; 100(6):L54-5. PubMed ID: 26047085
[No Abstract] [Full Text] [Related]
3. Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in the European Union.
Bellanger M; Demeneix B; Grandjean P; Zoeller RT; Trasande L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1256-66. PubMed ID: 25742515
[TBL] [Abstract][Full Text] [Related]
4. Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union.
Trasande L; Zoeller RT; Hass U; Kortenkamp A; Grandjean P; Myers JP; DiGangi J; Bellanger M; Hauser R; Legler J; Skakkebaek NE; Heindel JJ
J Clin Endocrinol Metab; 2015 Apr; 100(4):1245-55. PubMed ID: 25742516
[TBL] [Abstract][Full Text] [Related]
5. Obesity, diabetes, and associated costs of exposure to endocrine-disrupting chemicals in the European Union.
Legler J; Fletcher T; Govarts E; Porta M; Blumberg B; Heindel JJ; Trasande L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1278-88. PubMed ID: 25742518
[TBL] [Abstract][Full Text] [Related]
6. Male reproductive disorders, diseases, and costs of exposure to endocrine-disrupting chemicals in the European Union.
Hauser R; Skakkebaek NE; Hass U; Toppari J; Juul A; Andersson AM; Kortenkamp A; Heindel JJ; Trasande L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1267-77. PubMed ID: 25742517
[TBL] [Abstract][Full Text] [Related]
7. Burden of disease and costs of exposure to endocrine disrupting chemicals in the European Union: an updated analysis.
Trasande L; Zoeller RT; Hass U; Kortenkamp A; Grandjean P; Myers JP; DiGangi J; Hunt PM; Rudel R; Sathyanarayana S; Bellanger M; Hauser R; Legler J; Skakkebaek NE; Heindel JJ
Andrology; 2016 Jul; 4(4):565-72. PubMed ID: 27003928
[TBL] [Abstract][Full Text] [Related]
8. Female Reproductive Disorders, Diseases, and Costs of Exposure to Endocrine Disrupting Chemicals in the European Union.
Hunt PA; Sathyanarayana S; Fowler PA; Trasande L
J Clin Endocrinol Metab; 2016 Apr; 101(4):1562-70. PubMed ID: 27003299
[TBL] [Abstract][Full Text] [Related]
9. Human cost burden of exposure to endocrine disrupting chemicals. A critical review.
Bond GG; Dietrich DR
Arch Toxicol; 2017 Aug; 91(8):2745-2762. PubMed ID: 28528477
[TBL] [Abstract][Full Text] [Related]
10. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis.
Attina TM; Hauser R; Sathyanarayana S; Hunt PA; Bourguignon JP; Myers JP; DiGangi J; Zoeller RT; Trasande L
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):996-1003. PubMed ID: 27765541
[TBL] [Abstract][Full Text] [Related]
11. Comparison of methods for calculating the health costs of endocrine disrupters: a case study on triclosan.
Prichystalova R; Fini JB; Trasande L; Bellanger M; Demeneix B; Maxim L
Environ Health; 2017 Jun; 16(1):55. PubMed ID: 28599657
[TBL] [Abstract][Full Text] [Related]
12. Economic impacts of environmentally attributable childhood health outcomes in the European Union.
Bartlett ES; Trasande L
Eur J Public Health; 2014 Feb; 24(1):21-6. PubMed ID: 23748596
[TBL] [Abstract][Full Text] [Related]
13. Risk assessment of endocrine disrupting chemicals--introduction to this special issue.
van Ravenzwaay B; Dekant W; Vrijhof H
Toxicol Lett; 2013 Dec; 223(3):269-70. PubMed ID: 24140152
[No Abstract] [Full Text] [Related]
14. ECETOC Florence workshop on risk assessment of endocrine substances, including the potency concept.
Fegert I
Toxicol Lett; 2013 Dec; 223(3):310-4. PubMed ID: 23558296
[TBL] [Abstract][Full Text] [Related]
15. Exposure to endocrine disrupting chemicals and neurodevelopmental alterations.
Pinson A; Bourguignon JP; Parent AS
Andrology; 2016 Jul; 4(4):706-22. PubMed ID: 27285165
[TBL] [Abstract][Full Text] [Related]
16. Implications of research on endocrine disruption for the environmental risk assessment, regulation and monitoring of chemicals in the European Union.
Matthiessen P; Johnson I
Environ Pollut; 2007 Mar; 146(1):9-18. PubMed ID: 16996184
[TBL] [Abstract][Full Text] [Related]
17. Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation.
Grandjean P; Bellanger M
Environ Health; 2017 Dec; 16(1):123. PubMed ID: 29202828
[TBL] [Abstract][Full Text] [Related]
18. Health risk assessment procedures for endocrine disrupting compounds within different regulatory frameworks in the European Union.
Beronius A; Rudén C; Hanberg A; Håkansson H
Regul Toxicol Pharmacol; 2009 Nov; 55(2):111-22. PubMed ID: 19500631
[TBL] [Abstract][Full Text] [Related]
19. Dietary exposure to endocrine-active pesticides: Conflicting opinions in a European workshop.
Flynn K
Environ Int; 2011 Jul; 37(5):980-90. PubMed ID: 21497907
[No Abstract] [Full Text] [Related]
20. Response to A critique of the European Commission Document, "State of the Art Assessment of Endocrine Disrupters" by Rhomberg and colleagues--letter to the editor.
Kortenkamp A; Martin O; Evans R; Orton F; McKinlay R; Rosivatz E; Faust M
Crit Rev Toxicol; 2012 Oct; 42(9):787-9; author reply 790-1. PubMed ID: 22900988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
